Log in
NYSE:MMM

3M Competitors

$166.16
-3.64 (-2.14 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$164.39
Now: $166.16
$168.09
50-Day Range
$158.79
MA: $165.87
$172.38
52-Week Range
$114.04
Now: $166.16
$182.54
Volume2.70 million shs
Average Volume3.53 million shs
Market Capitalization$95.71 billion
P/E Ratio18.84
Dividend Yield3.46%
Beta0.97

Competitors

3M (NYSE:MMM) Vs. SYK, BDX, BSX, BAX, DXCM, and RMD

Should you be buying MMM stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to 3M, including Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), and ResMed (RMD).

Stryker (NYSE:SYK) and 3M (NYSE:MMM) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares Stryker and 3M's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.41$2.08 billion$8.2626.00
3M$32.14 billion2.98$4.57 billion$9.1018.26

3M has higher revenue and earnings than Stryker. 3M is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.1%. 3M pays an annual dividend of $5.88 per share and has a dividend yield of 3.5%. Stryker pays out 27.8% of its earnings in the form of a dividend. 3M pays out 64.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years and 3M has increased its dividend for 1 consecutive years.

Profitability

This table compares Stryker and 3M's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
3M16.38%46.86%11.03%

Institutional & Insider Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 64.6% of 3M shares are owned by institutional investors. 6.8% of Stryker shares are owned by company insiders. Comparatively, 0.4% of 3M shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, 3M has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Stryker and 3M, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291612.57
3M28202.00

Stryker currently has a consensus price target of $220.68, indicating a potential upside of 2.77%. 3M has a consensus price target of $169.9167, indicating a potential upside of 2.26%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than 3M.

Summary

Stryker beats 3M on 9 of the 17 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and 3M (NYSE:MMM) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Institutional & Insider Ownership

84.2% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 64.6% of 3M shares are owned by institutional investors. 0.1% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 0.4% of 3M shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Becton, Dickinson and and 3M, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
3M28202.00

Becton, Dickinson and currently has a consensus price target of $280.8571, indicating a potential upside of 16.06%. 3M has a consensus price target of $169.9167, indicating a potential upside of 2.26%. Given Becton, Dickinson and's stronger consensus rating and higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than 3M.

Earnings & Valuation

This table compares Becton, Dickinson and and 3M's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.29 billion4.06$1.23 billion$11.6820.72
3M$32.14 billion2.98$4.57 billion$9.1018.26

3M has higher revenue and earnings than Becton, Dickinson and. 3M is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Becton, Dickinson and and 3M's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.30%14.19%5.86%
3M16.38%46.86%11.03%

Volatility and Risk

Becton, Dickinson and has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, 3M has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Dividends

Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.3%. 3M pays an annual dividend of $5.88 per share and has a dividend yield of 3.5%. Becton, Dickinson and pays out 27.1% of its earnings in the form of a dividend. 3M pays out 64.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. 3M has increased its dividend for 1 consecutive years. 3M is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

3M (NYSE:MMM) and Boston Scientific (NYSE:BSX) are both large-cap multi-sector conglomerates companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

64.6% of 3M shares are held by institutional investors. Comparatively, 90.2% of Boston Scientific shares are held by institutional investors. 0.4% of 3M shares are held by company insiders. Comparatively, 0.7% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for 3M and Boston Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
3M28202.00
Boston Scientific031833.00

3M currently has a consensus price target of $169.9167, suggesting a potential upside of 2.26%. Boston Scientific has a consensus price target of $44.6522, suggesting a potential upside of 21.14%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than 3M.

Earnings and Valuation

This table compares 3M and Boston Scientific's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
3M$32.14 billion2.98$4.57 billion$9.1018.26
Boston Scientific$10.74 billion4.91$4.70 billion$1.5823.33

Boston Scientific has lower revenue, but higher earnings than 3M. 3M is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 3M and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
3M16.38%46.86%11.03%
Boston Scientific39.18%12.86%5.76%

Volatility & Risk

3M has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Boston Scientific beats 3M on 9 of the 14 factors compared between the two stocks.

3M (NYSE:MMM) and Baxter International (NYSE:BAX) are both large-cap multi-sector conglomerates companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

64.6% of 3M shares are held by institutional investors. Comparatively, 84.2% of Baxter International shares are held by institutional investors. 0.4% of 3M shares are held by company insiders. Comparatively, 0.1% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for 3M and Baxter International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
3M28202.00
Baxter International041402.78

3M currently has a consensus price target of $169.9167, suggesting a potential upside of 2.26%. Baxter International has a consensus price target of $96.4118, suggesting a potential upside of 20.50%. Given Baxter International's stronger consensus rating and higher probable upside, analysts plainly believe Baxter International is more favorable than 3M.

Earnings and Valuation

This table compares 3M and Baxter International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
3M$32.14 billion2.98$4.57 billion$9.1018.26
Baxter International$11.36 billion3.56$1.00 billion$3.3124.17

3M has higher revenue and earnings than Baxter International. 3M is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 3M and Baxter International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
3M16.38%46.86%11.03%
Baxter International8.10%20.75%8.81%

Risk & Volatility

3M has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Dividends

3M pays an annual dividend of $5.88 per share and has a dividend yield of 3.5%. Baxter International pays an annual dividend of $0.98 per share and has a dividend yield of 1.2%. 3M pays out 64.6% of its earnings in the form of a dividend. Baxter International pays out 29.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. 3M has raised its dividend for 1 consecutive years. 3M is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

3M beats Baxter International on 10 of the 17 factors compared between the two stocks.

3M (NYSE:MMM) and DexCom (NASDAQ:DXCM) are both large-cap multi-sector conglomerates companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

64.6% of 3M shares are held by institutional investors. Comparatively, 97.5% of DexCom shares are held by institutional investors. 0.4% of 3M shares are held by company insiders. Comparatively, 0.7% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for 3M and DexCom, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
3M28202.00
DexCom141502.70

3M currently has a consensus price target of $169.9167, suggesting a potential upside of 2.26%. DexCom has a consensus price target of $400.2105, suggesting a potential downside of 4.26%. Given 3M's higher probable upside, equities analysts plainly believe 3M is more favorable than DexCom.

Earnings and Valuation

This table compares 3M and DexCom's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
3M$32.14 billion2.98$4.57 billion$9.1018.26
DexCom$1.48 billion27.11$101.10 million$1.84227.17

3M has higher revenue and earnings than DexCom. 3M is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

3M has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, DexCom has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares 3M and DexCom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
3M16.38%46.86%11.03%
DexCom11.93%29.01%10.82%

Summary

3M beats DexCom on 8 of the 14 factors compared between the two stocks.

3M (NYSE:MMM) and ResMed (NYSE:RMD) are both large-cap multi-sector conglomerates companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Insider and Institutional Ownership

64.6% of 3M shares are owned by institutional investors. Comparatively, 69.4% of ResMed shares are owned by institutional investors. 0.4% of 3M shares are owned by company insiders. Comparatively, 1.3% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for 3M and ResMed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
3M28202.00
ResMed36201.91

3M presently has a consensus price target of $169.9167, suggesting a potential upside of 2.26%. ResMed has a consensus price target of $186.6667, suggesting a potential upside of 3.40%. Given ResMed's higher probable upside, analysts clearly believe ResMed is more favorable than 3M.

Earnings & Valuation

This table compares 3M and ResMed's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
3M$32.14 billion2.98$4.57 billion$9.1018.26
ResMed$2.96 billion8.85$621.67 million$4.7637.93

3M has higher revenue and earnings than ResMed. 3M is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Dividends

3M pays an annual dividend of $5.88 per share and has a dividend yield of 3.5%. ResMed pays an annual dividend of $1.56 per share and has a dividend yield of 0.9%. 3M pays out 64.6% of its earnings in the form of a dividend. ResMed pays out 32.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. 3M has raised its dividend for 1 consecutive years and ResMed has raised its dividend for 7 consecutive years.

Volatility & Risk

3M has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, ResMed has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Profitability

This table compares 3M and ResMed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
3M16.38%46.86%11.03%
ResMed21.02%30.34%15.73%

Summary

ResMed beats 3M on 9 of the 16 factors compared between the two stocks.


3M Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Stryker logo
SYK
Stryker
1.9$214.74-3.3%$80.49 billion$14.88 billion51.01Upcoming Earnings
Becton, Dickinson and logo
BDX
Becton, Dickinson and
1.7$242.00-0.7%$70.15 billion$17.29 billion87.05
Boston Scientific logo
BSX
Boston Scientific
2.1$36.86-0.8%$52.73 billion$10.74 billion13.07Upcoming Earnings
Baxter International logo
BAX
Baxter International
2.0$80.01-1.3%$40.50 billion$11.36 billion24.17Upcoming Earnings
DexCom logo
DXCM
DexCom
1.5$418.00-1.7%$40.02 billion$1.48 billion190.87
ResMed logo
RMD
ResMed
1.6$180.53-1.4%$26.16 billion$2.96 billion42.28Upcoming Earnings
Insulet logo
PODD
Insulet
1.4$253.53-1.6%$16.64 billion$738.20 million905.50
Teleflex logo
TFX
Teleflex
1.5$357.36-2.5%$16.62 billion$2.60 billion35.17Upcoming Earnings
ABIOMED logo
ABMD
ABIOMED
1.2$288.32-2.4%$12.99 billion$840.88 million83.09Upcoming Earnings
Novocure logo
NVCR
Novocure
1.5$121.50-1.9%$12.28 billion$351.32 million1,012.58Upcoming Earnings
Penumbra logo
PEN
Penumbra
1.6$236.71-0.3%$8.55 billion$547.41 million816.27Upcoming Earnings
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.1$116.91-1.5%$7.12 billion$362.30 million-155.88
Irhythm Technologies logo
IRTC
Irhythm Technologies
1.2$218.44-0.8%$6.30 billion$214.55 million-88.08
Hill-Rom logo
HRC
Hill-Rom
1.9$91.51-1.0%$6.10 billion$2.91 billion29.52
Haemonetics logo
HAE
Haemonetics
1.5$106.50-0.4%$5.40 billion$988.48 million57.57
Nevro logo
NVRO
Nevro
1.2$156.74-3.3%$5.38 billion$390.26 million-52.07Insider Selling
Globus Medical logo
GMED
Globus Medical
1.8$53.77-0.2%$5.26 billion$785.37 million62.52Upcoming Earnings
Integra LifeSciences logo
IART
Integra LifeSciences
1.5$47.47-3.4%$4.00 billion$1.52 billion-1,582.33Upcoming Earnings
ICU Medical logo
ICUI
ICU Medical
1.3$190.30-1.3%$3.98 billion$1.27 billion49.30
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.0$125.48-1.0%$3.36 billion$82.05 million-55.28Upcoming Earnings
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.8$48.49-1.0%$2.69 billion$994.85 million-89.79Upcoming Earnings
NuVasive logo
NUVA
NuVasive
1.6$50.93-2.8%$2.61 billion$1.17 billion-424.42Upcoming Earnings
Glaukos logo
GKOS
Glaukos
0.9$57.75-0.9%$2.58 billion$236.98 million-34.58
SWAV
ShockWave Medical
1.1$72.35-0.7%$2.46 billion$42.93 million-34.45
Cantel Medical logo
CMD
Cantel Medical
1.5$50.62-2.9%$2.13 billion$1.02 billion123.47
SILK
Silk Road Medical
0.9$60.11-3.0%$2.02 billion$63.35 million-51.38
AXNX
Axonics Modulation Technologies
1.4$49.93-0.0%$1.97 billion$13.82 million-19.13
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.0$10.45-4.8%$1.75 billion$4.11 million-6.08
AtriCure logo
ATRC
AtriCure
1.6$37.25-1.9%$1.67 billion$230.81 million-28.87
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$38.76-0.8%$1.56 billion$236.54 million-49.69Heavy News Reporting
Atrion logo
ATRI
Atrion
0.6$645.00-1.6%$1.18 billion$155.07 million34.04Heavy News Reporting
OraSure Technologies logo
OSUR
OraSure Technologies
1.1$15.92-6.3%$1.14 billion$154.60 million-530.49Analyst Upgrade
High Trading Volume
Unusual Options Activity
Luminex logo
LMNX
Luminex
1.8$21.89-2.5%$1.01 billion$334.64 million95.18Analyst Upgrade
Cerus logo
CERS
Cerus
1.6$5.95-6.6%$988.72 million$74.65 million-13.52Upcoming Earnings
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$47.57-3.1%$929.95 million$72.55 million-34.47
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.6$11.41-1.0%$810.92 million$88.02 million-20.37Upcoming Earnings
VAPO
Vapotherm
1.9$30.74-3.6%$786.02 million$48.10 million-13.60
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.4$38.15-3.0%$740.61 million$189.49 million-84.78Upcoming Earnings
CryoLife logo
CRY
CryoLife
2.2$18.96-2.0%$717.79 million$276.22 million-63.20
Alphatec logo
ATEC
Alphatec
1.6$8.89-7.3%$690.74 million$113.43 million-7.94
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.8$33.23-1.2%$672.14 million$117.23 million41.02Upcoming Earnings
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$33.06-1.3%$638.98 million$459.95 million-28.02
SIBN
SI-Bone
1.3$20.88-6.2%$597.79 million$67.30 million-12.07Upcoming Earnings
Heavy News Reporting
Surmodics logo
SRDX
Surmodics
1.4$39.80-2.8%$541.52 million$100.08 million71.07Upcoming Earnings
Analyst Downgrade
Intersect ENT logo
XENT
Intersect ENT
1.5$15.96-1.0%$521.92 million$109.14 million-8.36Upcoming Earnings
Analyst Revision
Heavy News Reporting
Antares Pharma logo
ATRS
Antares Pharma
1.8$2.97-0.0%$493.30 million$123.86 million74.27
RCEL
AVITA MED LTD/S
1.3$22.86-3.1%$492.68 million$14.26 million-11.04
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$34.64-1.6%$492.13 million$114.51 million55.87
AngioDynamics logo
ANGO
AngioDynamics
2.3$11.00-0.6%$417.45 million$264.16 million-2.48
Co-Diagnostics logo
CODX
Co-Diagnostics
1.4$14.04-11.3%$394.29 million$220,000.0078.00
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.